Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
Countries: Japan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
Multiregional Population-Based Cohort Study for Evaluation of the Association Between Herpes Zoster and mRNA Vaccinations for Severe Acute Respiratory Syndrome Coronavirus-2: The VENUS Study
CONCLUSIONS: No increased risk of HZ was found after BNT162b2 vaccination in the overall study population. However, an increased risk was observed in the younger subgroup.PMID:37404955 | PMC:PMC10316690 | DOI:10.1093/ofid/ofad274
Source: Herpes - July 5, 2023 Category: Infectious Diseases Authors: Chieko Ishiguro Wataru Mimura Yukari Uemura Megumi Maeda Fumiko Murata Haruhisa Fukuda Source Type: research
Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan
CONCLUSIONS: Varicella incidence and healthcare resource use were largely affected by the routine immunization program and infection prevention measures against COVID-19, while these impacts on herpes zoster were relatively small. Our study indicates that immunization and infection prevention measures largely changed pediatric infectious disease practices.PMID:37400282 | DOI:10.1016/j.vaccine.2023.06.054
Source: Herpes - July 3, 2023 Category: Infectious Diseases Authors: Kazuhiro Uda Yusuke Okubo Mitsuru Tsuge Hirokazu Tsukahara Isao Miyairi Source Type: research
Risk of herpes zoster according to past history in the general population: The Japanese Shozu herpes zoster study
J Dermatol. 2023 Jun 19. doi: 10.1111/1346-8138.16828. Online ahead of print.ABSTRACTImmunity is known to persist after vaccination for varicella zoster virus, but the duration of immunity in patients who develop herpes zoster (HZ) remains unknown. To investigate the association between a past history of HZ and its occurrence in the general population. The Shozu HZ (SHEZ) cohort study included data for 12 299 individuals aged ≥50 years with information on their HZ history. Cross-sectional and 3-year follow-up studies were carried out to analyze the associations between a history of HZ (yes <10 years, yes ≥10 years, ...
Source: Herpes - June 19, 2023 Category: Infectious Diseases Authors: Kazuhiro Kawahira Hironori Imano Keiko Yamada Yasuko Mori Hideo Asada Yoshinobu Okuno Koichi Yamanishi Hiroyasu Iso Source Type: research
Associations between income changes and the risk of herpes zoster: LIFE study
Soc Sci Med. 2023 May 22;328:115981. doi: 10.1016/j.socscimed.2023.115981. Online ahead of print.ABSTRACTEconomic stability is thought to be associated with health outcomes. Income changes may affect the occurrence of herpes zoster (HZ), which is a neurocutaneous disease caused by the varicella-zoster virus. This retrospective cohort study aimed to examine the associations between annual income changes and incident HZ in a Japanese population. The analysis was conducted using a database of public health insurance claims data linked with administrative data containing income levels. The study population comprised 48,317 mid...
Source: Herpes - June 3, 2023 Category: Infectious Diseases Authors: Hiroaki Onizuka Haruhisa Fukuda Source Type: research
Trend in the Numbers of Hospitalized Patients With Varicella, Herpes Zoster, and Ischemic Stroke in Japanese Individuals & lt;20 Years of Age Before and After Implementation of Universal Varicella Vaccination
Pediatr Infect Dis J. 2023 Mar 20. doi: 10.1097/INF.0000000000003907. Online ahead of print.ABSTRACTSeveral studies have shown an association between varicella-zoster virus infection and ischemic stroke. We analyzed the trends in the numbers of patients with varicella, herpes zoster and ischemic stroke before and after the universal vaccination program using a Japanese database of hospitalized patients. The number of patients with varicella decreased but those of herpes zoster and ischemic stroke did not change.PMID:36996309 | DOI:10.1097/INF.0000000000003907
Source: Herpes - March 30, 2023 Category: Infectious Diseases Authors: Soichiro Ishimaru Nobuaki Michihata Yoshiki Kawamura Kazuaki Uda Hiroki Matsui Kiyohide Fushimi Hideo Yasunaga Tetsushi Yoshikawa Source Type: research
Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study
Conclusion: Freeze-dried live attenuated varicella-zoster vaccine reduces the risk of HZ regardless of age, sex, or comorbidities.PMID:36851138 | DOI:10.3390/vaccines11020259
Source: Herpes - February 28, 2023 Category: Infectious Diseases Authors: Kazuhiro Matsumoto Satoko Ohfuji Kana Inohara Masateru Akechi Hiroko Kumashiro Motoki Ishibashi Shin Irie Yoshio Hirota Source Type: research
Longitudinal changes in cell-mediated immunity after varicella-zoster virus skin test in the general population; Shozu Herpes Zoster Study: SHEZ Study
CONCLUSION: Soluble antigen by VZV skin test enhanced VZV-specific cell-mediated immunity, and it persisted for at least one year. In addition, the inoculation with inactivated antigens every year by VZV skin test continued to enhance VZV-specific cell-mediated immunity after 2 and 3 years. This article is protected by copyright. All rights reserved.PMID:36418204 | DOI:10.1002/jmv.28336
Source: Herpes - November 23, 2022 Category: Infectious Diseases Authors: Daisuke Ikeda Hironori Imano Yasuko Mori Hideo Asada Koichi Yamanishi Yoshinobu Okuno Hiroyasu Iso Source Type: research
Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
IDCases. 2022 Jul 13;29:e01563. doi: 10.1016/j.idcr.2022.e01563. eCollection 2022.ABSTRACTAs a result of the COVID-19 pandemic, mRNA vaccination has become widespread. Recently, it has been suggested that instances of herpes zoster increase following mRNA COVID-19 vaccination. Herein, we describe the first case of zoster sine herpete (ZSH) after mRNA vaccination for COVID-19. A 60-year-old Japanese immunocompetent man presented with fever, fatigue, headache, cervical pain, and lumbar pain, which developed after receiving a second dose of BNT162b2 mRNA COVID-19 vaccination. Whereas most symptoms improved with symptomatic tr...
Source: Herpes - July 20, 2022 Category: Infectious Diseases Authors: Ryutaro Tanizaki Yayoi Miyamatsu Source Type: research
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
CONCLUSION: Vaccination against HZ with RZV is cost-effective compared with no vaccination in Japanese adults aged 65 years.PMID:35668295 | DOI:10.1007/s13555-022-00744-8
Source: Herpes - June 6, 2022 Category: Infectious Diseases Authors: Lida Teng Akiko Mizukami Cheryl Ng Nikolaos Giannelos Desmond Curran Tomohide Sato Christa Lee Taizo Matsuki Source Type: research
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
